Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics (NQ: HZNP )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Horizon Therapeutics

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
This Is What Whales Are Betting On Horizon Therapeutics
Via Benzinga
Stock Market Rally Gains Momentum As Treasury Yields Slide; Tesla Unveils Model 3 Upgrade: Weekly Review
Tesla unveiled an updated Model 3, but also slashed Model S, X prices. 
Via Investor's Business Daily
Amgen-Horizon Therapeutics $28B Acquisition: Federal Trade Commission Gives Green Signal
The U.S. Federal Trade Commission (FTC) has approved drug manufacturer Amgen Inc (NASDAQ: AMGN) to proceed with its $27.8 billion acquisition of Horizon Therapeutics Plc (NASDAQ: HZNP).  
Via Benzinga
Amgen, Horizon Therapeutics Stocks Jump After FTC Clears Their $28 Billion Marriage
The deal can now close in the fourth quarter. 
Via Investor's Business Daily
Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition
From Horizon Therapeutics plc and Amgen
Via Business Wire
Peering Into Horizon Therapeutics's Recent Short Interest
Via Benzinga
P/E Ratio Insights for Horizon Therapeutics
Via Benzinga
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Is This the Green Light Biotech Stocks Have Been Waiting For?
It looks like the Federal Trade Commission will give up on its attempt to block Amgen's acquisition of Horizon Therapeutics. 
Via The Motley Fool
Nasdaq, S&P 500 Futures Flatline Ahead Of JOLTS, House Price Data; Why This Analyst Recommends 'Buying Weakness Than Selling Rallies'
Via Benzinga
Topics Stocks
Exposures US Equities
Is Amgen Stock a Top Buy and Hold?
The biotech checks several important boxes for long-term shareholders. 
Via The Motley Fool
Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories
Reuters 
Via Benzinga
US Stocks Seen Opening Firmer In New Week's 1st Session As Traders Look To Week's Key Data; Analyst Constructive Despite Bearish Signals
Via Benzinga
FTC Takes A Rare Step Back, Pauses Legal Battle With Amgen Over $28B Horizon Deal
The Federal Trade Commission (FTC) decided to momentarily halt its challenge against pharmaceutical giant Amgen, Inc (NASDAQ: AMGN), concerning its proposed acquisition of Horizon Therapeutics PLC... 
Via Benzinga
Horizon Therapeutics Jumps On A New FTC Development In The Amgen Takeover Battle
The FTC is pulling back somewhat on its effort to challenge the deal. 
Via Investor's Business Daily
Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy Groups
From Horizon Therapeutics plc
Via Business Wire
Could Amgen Stock Help You Become a Millionaire?
Its pending acquisition of Horizon Therapeutics could make the company much bigger. 
Via The Motley Fool
Drinks, Chips & Drugs: A Surprising List of 10-Year Stock Winners
A handful of large caps have taken things to another level. These three stocks have blown past the herd — and may be market leaders for years to come. 
Via MarketBeat
Topics Bankruptcy Economy
Exposures Economy Financial Legal
Horizon Therapeutics plc - Rule 2.12 Announcement
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results
From Horizon Therapeutics plc
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Is Growth Priced into Amgen Stock after Earnings Beat?
Amgen earnings delivered a solid earnings report after the market closed but analyst sentiment suggests that growth may already be priced into AMGN stock. 
Via MarketBeat
Amgen Beats Expectations, Raises Outlook With Horizon Takeover In The Wings
The massive biotech company also beat second-quarter expectations Thursday. 
Via Investor's Business Daily
Amgen To Report Q2 Earnings: Here's What To Expect
Amgen will report second-quarter 2023 results on Aug. 3, after the market close. 
Via Talk Markets
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated
Earlier today, Biogen Inc (NASDAQ: BIIB) agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of  
Via Benzinga
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients
From Horizon Therapeutics plc
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Stocks Higher As Energy Sector Shines
Stocks are moving higher today, as the surging energy sector gives the market a boost. 
Via Talk Markets
Horizon Therapeutics' Lupus Candidate Flunks Mid-Stage Study
Horizon Therapeutics plc's (NASDAQ: HZNP) Phase 2 trial evaluating daxdilimab for Systemic Lupus Erythematosus (SLE) did not  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback